Safety and Efficacy of KITE-439 in HLA-A*02:01+ Adults With Relapsed/Refractory HPV16+ Cancers
Status:
Active, not recruiting
Trial end date:
2021-12-01
Target enrollment:
Participant gender:
Summary
This study has 2 parts: Phase 1A and Phase 1B. The primary objectives of Phase 1A are to
evaluate the safety of KITE-439 and to determine a recommended Phase 1B dose. The primary
objective of Phase 1B is to estimate the efficacy of KITE-439 in human leukocyte antigen
(HLA)-A*02:01+ adults with relapsed/refractory human papillomavirus (HPV)16+ cancers.